ICAM-1 orchestrates the abscopal effect of tumor radiotherapy.
Yang Zhao, Ting Zhang, Yanpu Wang...
https://pubmed.ncbi.nlm.nih.gov/33785590Actively Recruiting
Early Phase 1
Age: 18Years - 80Years
All Genders
ID04596670
68Ga-ICAM-1pep PET/CT Imaging of Tumor Responses to Radiotherapy in Cancer Patients
Led by Peking University Cancer Hospital & Institute · Updated on 2024-08-19
20
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
P
Peking University Cancer Hospital & Institute
Lead Sponsor
P
Peking University Health Science Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to evaluate the use of a new imaging agent called 68Ga-ICAM-1pep in cancer patients undergoing radiotherapy. Researchers want to see if this agent can help predict the abscopal effect, a phenomenon where radiotherapy affects tumors outside the treated area. The study focuses on patients with various cancers such as lung, esophagus, and cervical cancer, and it is an early-phase clinical trial investigating this new approach. Participants will receive a single intravenous dose of 2.96 MBq/kg of 68Ga-ICAM-1pep. PET/CT scans will be performed about one hour after the injection. There are two groups: patients who have not yet received radiotherapy and those who have completed radiotherapy. Imaging will be done before and during radiotherapy to observe tumor responses. During the study, participants will undergo PET/CT scans covering from the head to the upper thigh. Researchers will measure the standardized uptake values (SUVs) of 68Ga-ICAM-1pep before treatment and monitor changes during radiotherapy, about 3 to 4 weeks after it begins. The study includes monitoring for compliance with imaging procedures and overall safety until the study ends in late 2025.
CONDITIONS
Brief Title
68Ga-ICAM-1pep PET/CT in Cancer Patients
Who Can Participate
Age: 18Years - 80Years
All Genders
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- ECOG performance status score of 0 or 1
- Suspected or confirmed lung cancer, esophagus cancer, cervical cancer, or other cancers recommended for PET/CT imaging by clinicians
You will not qualify if you...
- Pregnant or nursing
- Severe liver or kidney dysfunction
- Low white blood cell count (less than 3 x 10^9/L)
- Inability to comply with PET/CT imaging procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - 1 day
Participants undergo PET/CT imaging with the 68Ga-ICAM-1pep radiotracer before radiotherapy to assess tumor responses.
1 visit (in-person)
Treatment
Duration - 3 to 4 weeks
Participants receive radiotherapy as prescribed by their clinicians.
Diagnostic Evaluation
Duration - 1 day
Participants undergo PET/CT imaging with the 68Ga-ICAM-1pep radiotracer after radiotherapy to evaluate changes in tumor responses.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Loading map...
Research Team
T
Ting Zhang
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here